Genentech: Tim Heffron | Associate Director, Principal Scientist, Discovery Chemistry

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/tim-heffron

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"Each day we work to extend and improve lives."

Years at Genentech

I joined the Discovery Chemistry department at Genentech as a Medicinal Chemist in 2005 after completing my PhD in organic chemistry at MIT. I now lead interdisciplinary teams focused on the discovery of new drugs to extend and improve people’s lives.

Featured Publication

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.

ACS Med Chem Lett. 2016 Feb 16;7(4):351-6.

Heffron TP, Ndubaku CO, Salphati L, Alicke B, Cheong J, Drobnick J, Edgar K, Gould SE, Lee LB, Lesnick JD, Lewis C, Nonomiya J, Pang J, Plise EG, Sideris S, Wallin J, Wang L, Zhang X, Olivero AG.

View Abstract

As a chemist, my work can focus on designing drugs directed to whatever target is most compelling from a biological point of view without being confined to a particular therapeutic area. In my time at Genentech I have contributed to programs directed toward the discovery of new therapeutics for oncology (including cancer immunotherapy), neuro-oncology, neurology, and ophthalmology indications. Each program brings unique scientific challenges and a need to innovate to discover new medicines.

Massachusetts Institute of Technology, Organic Chemistry, Ph. D. – 2005
Yale University, Chemistry, B.S. – 2000

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Tim Heffron

Associate Director, Principal Scientist, Discovery Chemistry

Featured Publication

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

Tim Heffron

Associate Director, Principal Scientist, Discovery Chemistry

Featured Publication

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.